Date: 2013-06-12
Type of information: Collaboration agreement
Compound: validation of biomarkers for the early detection of lung and colorectal cancers
Company: Abcodia (UK) Austrian Institute of Technology (Austria)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease: lung cancer, colorectal cancer
Details: * On June 12, 2013, Abcodia, a UK biomarker validation company with a focus on cancer screening, has announced a collaboration with the AIT Austrian Institute of Technology which will focus on the validation of biomarkers for the early detection of lung and colorectal cancers. Through an exclusive commercial licenseto the UKCTOCS biobank, the company is able to use the 500,000 samples from this population cohort to develop a pipeline of diagnostic products for the early detection of a range of cancers. Through this exclusive access to a unique longitudinal collection of serum samples derived from a population cohort involved in the UKCTOCS trial, Abcodia and AIT will work closely to design a series of longitudinal studies to validate panels of biomarkers for lung cancer and colorectal cancer. The collaboration aims to generate a package of data that will support the licensing of the IP to a commercial partner.
Financial terms:
Latest news:
